Cargando…

Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer

Targeted therapy and immunotherapy have changed the treatment modes for advanced non-small cell lung cancer (NSCLC), moving from second-line to first-line treatment and significantly extending patients’ survival. Surgery and chemoradiotherapy remain the main treatment options for patients with local...

Descripción completa

Detalles Bibliográficos
Autores principales: Sa, Huanlan, Song, Peng, Ma, Kewei, Gao, Yong, Zhang, Li, Wang, Deqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781597/
https://www.ncbi.nlm.nih.gov/pubmed/31632066
http://dx.doi.org/10.2147/OTT.S222412
_version_ 1783457401548046336
author Sa, Huanlan
Song, Peng
Ma, Kewei
Gao, Yong
Zhang, Li
Wang, Deqiang
author_facet Sa, Huanlan
Song, Peng
Ma, Kewei
Gao, Yong
Zhang, Li
Wang, Deqiang
author_sort Sa, Huanlan
collection PubMed
description Targeted therapy and immunotherapy have changed the treatment modes for advanced non-small cell lung cancer (NSCLC), moving from second-line to first-line treatment and significantly extending patients’ survival. Surgery and chemoradiotherapy remain the main treatment options for patients with locally advanced lung cancer, but recurrence and metastasis still occur in some patients. The survival rates of conventional perioperative chemotherapy among NSCLC patients have increased by only 5%. Therefore, more studies have begun to explore targeted and immune neoadjuvant/adjuvant therapies in early-stage and locally advanced NSCLC, and the relevant clinical research data have shown good efficacy and safety profiles. This article summarizes several clinical studies of critical importance.
format Online
Article
Text
id pubmed-6781597
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67815972019-10-18 Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer Sa, Huanlan Song, Peng Ma, Kewei Gao, Yong Zhang, Li Wang, Deqiang Onco Targets Ther Review Targeted therapy and immunotherapy have changed the treatment modes for advanced non-small cell lung cancer (NSCLC), moving from second-line to first-line treatment and significantly extending patients’ survival. Surgery and chemoradiotherapy remain the main treatment options for patients with locally advanced lung cancer, but recurrence and metastasis still occur in some patients. The survival rates of conventional perioperative chemotherapy among NSCLC patients have increased by only 5%. Therefore, more studies have begun to explore targeted and immune neoadjuvant/adjuvant therapies in early-stage and locally advanced NSCLC, and the relevant clinical research data have shown good efficacy and safety profiles. This article summarizes several clinical studies of critical importance. Dove 2019-10-03 /pmc/articles/PMC6781597/ /pubmed/31632066 http://dx.doi.org/10.2147/OTT.S222412 Text en © 2019 Sa et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Sa, Huanlan
Song, Peng
Ma, Kewei
Gao, Yong
Zhang, Li
Wang, Deqiang
Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
title Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
title_full Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
title_fullStr Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
title_full_unstemmed Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
title_short Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
title_sort perioperative targeted therapy or immunotherapy in non-small-cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781597/
https://www.ncbi.nlm.nih.gov/pubmed/31632066
http://dx.doi.org/10.2147/OTT.S222412
work_keys_str_mv AT sahuanlan perioperativetargetedtherapyorimmunotherapyinnonsmallcelllungcancer
AT songpeng perioperativetargetedtherapyorimmunotherapyinnonsmallcelllungcancer
AT makewei perioperativetargetedtherapyorimmunotherapyinnonsmallcelllungcancer
AT gaoyong perioperativetargetedtherapyorimmunotherapyinnonsmallcelllungcancer
AT zhangli perioperativetargetedtherapyorimmunotherapyinnonsmallcelllungcancer
AT wangdeqiang perioperativetargetedtherapyorimmunotherapyinnonsmallcelllungcancer